Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate ...

Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...

Vor Biopharma Inc. offers a high-risk, high-reward play on U.S. commercialization of telitacicept, a dual-target autoimmune drug approved in China. Complex warrant issuances and reverse stock split ...

Investing.com - JPMorgan has initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a price target of $43.00, highlighting the potential of the company’s telitacicept ...

The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

IRAEmpire has released a new and updated list of the best crypto IRA companies in the US to help consumers make better-informed decisions. DALLAS, TEXAS / ACCESS Newswire / December 26, 2025 / More Am ...

Abstract: I welcome you to the fourth issue of the IEEE Communications Surveys and Tutorials in 2021. This issue includes 23 papers covering different aspects of communication networks. In particular, ...